No photo of Ramesk K Ramanathan

View Scopus Profile

Ramesk K Ramanathan, MD

  • 15416 Citations
  • 52 Scopus h-Index
1978 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

2020

Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

Ramanathan, R. K., Von Hoff, D. D., Eskens, F., Blumenschein, G., Richards, D., Genvresse, I., Reschke, S., Granvil, C., Skubala, A., Peña, C. & Mross, K., Apr 1 2020, In : Targeted Oncology. 15, 2, p. 163-174 12 p.

Research output: Contribution to journal › Article

Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors

Strickler, J. H., LoRusso, P., Salgia, R., Kang, Y. K., Yen, C. J., Lin, C. C., Ansell, P., Motwani, M., Wong, S., Yue, H., Wang, L., Reilly, E., Afar, D., Naumovski, L. & Ramanathan, R. K., May 1 2020, In : Molecular cancer therapeutics. 19, 5, p. 1210-1217 8 p.

Research output: Contribution to journal › Article

Open Access

Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours

Mahalingam, D., Patel, M. R., Sachdev, J. C., Hart, L. L., Halama, N., Ramanathan, R. K., Sarantopoulos, J., Völkel, D., Youssef, A., de Jong, F. A. & Tsimberidou, A. M., Jan 1 2020, (Accepted/In press) In : British Journal of Clinical Pharmacology.

Research output: Contribution to journal › Article

Open Access
1 Scopus citations
2019

A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer

Gorbunova, V., Beck, J. T., Hofheinz, R. D., Garcia-Alfonso, P., Nechaeva, M., Cubillo Gracian, A., Mangel, L., Elez Fernandez, E., Deming, D. A., Ramanathan, R. K., Torres, A. H., Sullivan, D., Luo, Y. & Berlin, J. D., Jan 22 2019, In : British journal of cancer. 120, 2, p. 183-189 7 p.

Research output: Contribution to journal › Article

4 Scopus citations

A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer

Ramanathan, R. K., Thomas, G. W., Khorana, A. A., Shah, S., Zhou, C., Wong, S., Cole, G., James, D. & Gabrail, N. Y., Apr 1 2019, In : Oncology (Switzerland). 96, 4, p. 217-222 6 p.

Research output: Contribution to journal › Article

Open Access
4 Scopus citations

Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer (British Journal of Cancer, (2019), 120, 2, (183-189), 10.1038/s41416-018-0343-z)

Gorbunova, V., Beck, J. T., Hofheinz, R. D., Garcia-Alfonso, P., Nechaeva, M., Gracian, A. C., Mangel, L., Fernandez, E. E., Deming, D. A., Ramanathan, R. K., Torres, A. H., Sullivan, D., Luo, Y. & Berlin, J. D., Aug 27 2019, In : British journal of cancer. 121, 5, p. 429-430 2 p.

Research output: Contribution to journal › Comment/debate

Open Access

Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial

Shroff, R. T., Javle, M. M., Xiao, L., Kaseb, A. O., Varadhachary, G. R., Wolff, R. A., Raghav, K. P. S., Iwasaki, M., Masci, P., Ramanathan, R. K., Ahn, D. H., Bekaii-Saab, T. S. & Borad, M. J., Jun 2019, In : JAMA Oncology. 5, 6, p. 824-830 7 p.

Research output: Contribution to journal › Article

24 Scopus citations

Hepatocytes direct the formation of a pro-metastatic niche in the liver

Lee, J. W., Stone, M. L., Porrett, P. M., Thomas, S. K., Komar, C. A., Li, J. H., Delman, D., Graham, K., Gladney, W. L., Hua, X., Black, T. A., Chien, A. L., Majmundar, K. S., Thompson, J. C., Yee, S. S., O’Hara, M. H., Aggarwal, C., Xin, D., Shaked, A., Gao, M. & 9 others, Liu, D., Borad, M. J., Ramanathan, R. K., Carpenter, E. L., Ji, A., de Beer, M. C., de Beer, F. C., Webb, N. R. & Beatty, G. L., Mar 14 2019, In : Nature. 567, 7747, p. 249-252 4 p.

Research output: Contribution to journal › Article

39 Scopus citations

Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma

De Jesus-Acosta, A., Sugar, E. A., O’Dwyer, P. J., Ramanathan, R. K., Von Hoff, D. D., Rasheed, Z., Zheng, L., Begum, A., Anders, R., Maitra, A., McAllister, F., Rajeshkumar, N. V., Yabuuchi, S., de Wilde, R. F., Batukbhai, B., Sahin, I. & Laheru, D. A., Jan 1 2019, (Accepted/In press) In : British journal of cancer.

Research output: Contribution to journal › Article

2 Scopus citations

Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313

Ramanathan, R. K., McDonough, S. L., Philip, P. A., Hingorani, S. R., Lacy, J., Kortmansky, J. S., Thumar, J., Chiorean, E. G., Shields, A. F., Behl, D., Mehan, P. T., Gaur, R., Seery, T., Guthrie, K. A. & Hochster, H. S., Jan 1 2019, In : Journal of Clinical Oncology. 37, 13, p. 1062-1069 8 p.

Research output: Contribution to journal › Article

29 Scopus citations

Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment among Patients with Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial

Jameson, G. S., Borazanci, E., Babiker, H. M., Poplin, E., Niewiarowska, A. A., Gordon, M. S., Barrett, M. T., Rosenthal, A., Stoll-D'astice, A., Crowley, J., Shemanski, L., Korn, R. L., Ansaldo, K., Lebron, L., Ramanathan, R. K. & Von Hoff, D. D., Jan 1 2019, (Accepted/In press) In : JAMA Oncology.

Research output: Contribution to journal › Article

3 Scopus citations
2018

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

Berlin, J., Ramanathan, R. K., Strickler, J. H., Subramaniam, D. S., Marshall, J., Kang, Y. K., Hetman, R., Dudley, M. W., Zeng, J., Nickner, C., Xiong, H., Komarnitsky, P., Shepherd, S. P., Hurwitz, H. & Lenz, H. J., Mar 12 2018, (Accepted/In press) In : British Journal of Cancer. p. 1-9 9 p.

Research output: Contribution to journal › Article

4 Scopus citations

A phase II clinical investigation of BPM31510-IV (ubidecarenone) in patients with advanced pancreatic cancer

Niewiarowska, A. A., Lucius, D. M., Sarangarajan, R., Narain, N. R., Ramanathan, R., Ritch, P., Strauss, J., Kundranda, M. & Propper, D., Oct 1 2018, In : Annals of oncology : official journal of the European Society for Medical Oncology. 29, p. viii270

Research output: Contribution to journal › Article

Open Access

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors

Moschos, S. J., Sullivan, R. J., Hwu, W. J., Ramanathan, R. K., Adjei, A. A., Fong, P. C., Shapira-Frommer, R., Tawbi, H. A., Rubino, J., Rush, T. S., Zhang, D., Miselis, N. R., Samatar, A. A., Chun, P., Rubin, E. H., Schiller, J., Long, B. J., Dayananth, P., Carr, D., Kirschmeier, P. & 8 others, Bishop, W. R., Deng, Y., Cooper, A., Shipps, G. W., Moreno, B. H., Robert, L., Ribas, A. & Flaherty, K. T., Feb 22 2018, In : JCI Insight. 3, 4

Research output: Contribution to journal › Article

Open Access
31 Scopus citations

Emerging therapies and future directions in targeting the tumor stroma and immune system in the treatment of pancreatic adenocarcinoma

Ahn, D., Ramanathan, R. K. & Bekaii-Saab, T., Jun 11 2018, In : Cancers. 10, 6, 193.

Research output: Contribution to journal › Review article

3 Scopus citations

Erratum: Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours (British journal of cancer (2018) 118 2 (153-161))

Infante, J. R., Korn, R. L., Rosen, L. S., LoRusso, P., Dychter, S. S., Zhu, J., Maneval, D. C., Jiang, P., Shepard, H. M., Frost, G., Von Hoff, D. D., Borad, M. J. & Ramanathan, R. K., Jan 1 2018, In : British journal of cancer. 118, 2, p. e3

Research output: Contribution to journal › Comment/debate

Open Access

First-in-human phase I, dose-escalation and -expansion study of telisotuzumab vedotin, an antibody–drug conjugate targeting c-Met, in patients with advanced solid tumors

Strickler, J. H., Weekes, C. D., Nemunaitis, J., Ramanathan, R. K., Heist, R. S., Morgensztern, D., Angevin, E., Bauer, T. M., Yue, H., Motwani, M., Parikh, A., Reilly, E. B., Afar, D., Naumovski, L. & Kelly, K., Nov 20 2018, In : Journal of Clinical Oncology. 36, 33, p. 3298-3306 9 p.

Research output: Contribution to journal › Article

11 Scopus citations

Metastatic pancreatic cancer: ASCO clinical practice guideline update

Sohal, D. P. S., Kennedy, E. B., Khorana, A., Copur, M. S., Crane, C. H., Garrido-Laguna, I., Krishnamurthi, S., Moravek, C., O'Reilly, E. M., Philip, P. A., Ramanathan, R. K., Ruggiero, J. T., Shah, M. A., Urba, S., Uronis, H. E., Lau, M. W. & Laheru, D., Aug 20 2018, In : Journal of Clinical Oncology. 36, 24, p. 2545-2556 12 p.

Research output: Contribution to journal › Review article

39 Scopus citations

Novel immunotherapy strategies for hepatobiliary cancers

Deleon, T. T., Zhou, Y., Nagalo, B. M., Yokoda, R. T., Ahn, D. H., Ramanathan, R. K., Salomao, M. A., Aqel, B. A., Mahipal, A., Bekaii-Saab, T. S. & Borad, M. J., Sep 1 2018, In : Immunotherapy. 10, 12, p. 1077-1091 15 p.

Research output: Contribution to journal › Review article

Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma

Deleon, T. T., Ahn, D., Bogenberger, J. M., Anastasiadis, P. Z., Arora, M., Ramanathan, R. K., Aqel, B. A., Vasmatzis, G., Truty, M., Oklu, R., Bekaii-Saab, T. & Borad, M. J., Mar 1 2018, In : Future Oncology. 14, 6, p. 553-566 14 p.

Research output: Contribution to journal › Review article

11 Scopus citations

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours

Infante, J. R., Korn, R. L., Rosen, L. S., Lorusso, P., Dychter, S. S., Zhu, J., Maneval, D. C., Jiang, P., Shepard, H. M., Frost, G., Von Hoff, D. D., Borad, M. J. & Ramanathan, R. K., Jan 1 2018, In : British journal of cancer. 118, 2, p. 153-161 9 p.

Research output: Contribution to journal › Article

25 Scopus citations

Phase II study of BGJ398 in patients with FGFR-Altered advanced cholangiocarcinoma

Javle, M., Lowery, M., Shroff, R. T., Weiss, K. H., Springfeld, C., Borad, M. J., Ramanathan, R. K., Goyal, L., Sadeghi, S., Macarulla, T., El-Khoueiry, A., Kelley, R. K., Borbath, I., Choo, S. P., Oh, D. Y., Philip, P. A., Chen, L. T., Reungwetwattana, T., Van Cutsem, E., Yeh, K. H. & 9 others, Ciombor, K., Finn, R. S., Patel, A., Sen, S., Porter, D., Isaacs, R., Zhu, A. X., Abou-Alfa, G. K. & Bekaii-Saab, T., Jan 20 2018, In : Journal of Clinical Oncology. 36, 3, p. 276-282 7 p.

Research output: Contribution to journal › Article

127 Scopus citations

Phase I study of enavatuzumab, a first-in-class humanized monoclonal antibody targeting the TWEAK receptor, in patients with advanced solid tumors

Lam, E. T., Eckhardt, S. G., Messersmith, W., Jimeno, A., O'Bryant, C. L., Ramanathan, R. K., Weiss, G. J., Chadha, M., Oey, A., Ding, H. T., Culp, P. A., Keller, S. F., Zhao, V. Y., Tsao, L. C., Singhal, A., Holen, K. D. & Von Hoff, D., Jan 1 2018, In : Molecular Cancer Therapeutics. 17, 1, p. 215-221 7 p.

Research output: Contribution to journal › Article

4 Scopus citations
2017

18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer

Korn, R. L., Von Hoff, D. D., Borad, M. J., Renschler, M. F., McGovern, D., Curtis Bay, R. & Ramanathan, R. K., Aug 3 2017, In : Cancer Imaging. 17, 1, 23.

Research output: Contribution to journal › Article

4 Scopus citations

A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients

Ramanathan, R. K., Weiss, G. J., Posner, R. G., Rajeshkumar, N. V., Jameson, G., Aziz, M., Hoering, A., Bolejack, V., Maitra, A., Fulk, M., Stites, E. C., Hlavacek, W. S., Gatalica, Z., Xiu, J., Hidalgo, M., Von Hoff, D. D. & Barrett, M., Dec 1 2017, In : Journal of Gastrointestinal Oncology. 8, 6, p. 925-935 11 p.

Research output: Contribution to journal › Article

Clinical study of genomic drivers in pancreatic ductal adenocarcinoma

Barrett, M., Deiotte, R., Lenkiewicz, E., Malasi, S., Holley, T., Evers, L., Posner, R. G., Jones, T., Han, H., Sausen, M., Velculescu, V. E., Drebin, J., O'Dwyer, P., Jameson, G., Ramanathan, R. K. & Von Hoff, D. D., Aug 8 2017, In : British Journal of Cancer. 117, 4, p. 572-582 11 p.

Research output: Contribution to journal › Article

11 Scopus citations

Correlation between ferumoxytol uptake in tumor lesions by MRI and response to nanoliposomal irinotecan in patients with advanced solid tumors: A pilot study

Ramanathan, R. K., Korn, R. L., Raghunand, N., Sachdev, J. C., Newbold, R. G., Jameson, G., Fetterly, G. J., Prey, J., Klinz, S. G., Kim, J., Cain, J., Hendriks, B. S., Drummond, D. C., Bayever, E. & Fitzgerald, J. B., Jul 15 2017, In : Clinical Cancer Research. 23, 14, p. 3638-3648 11 p.

Research output: Contribution to journal › Article

56 Scopus citations

Development of new pharmaceutical therapies for pancreatic adenocarcinoma

Ramanathan, R. K., Nov 1 2017, In : Clinical Advances in Hematology and Oncology. 15, 11, p. 7-10 4 p.

Research output: Contribution to journal › Article

Immunotherapy in pancreatic cancer treatment: A new frontier

Thind, K., Padrnos, L. J., Ramanathan, R. K. & Borad, M. J., Jan 1 2017, In : Therapeutic Advances in Gastroenterology. 10, 1, p. 168-194 27 p.

Research output: Contribution to journal › Review article

35 Scopus citations

Molecular modeling and functional analysis of exome sequencing-derived variants of unknown significance identify a novel, constitutively active FGFR2 mutant in cholangiocarcinoma

Egan, J. B., Marks, D. L., Hogenson, T. L., Vrabel, A. M., Sigafoos, A. N., Tolosa, E. J., Carr, R. M., Safgren, S. L., Hesles, E. E., Almada, L. L., Romecin-Duran, P. A., Iguchi, E., Ala'Aldeen, A., Kocher, J. P. A., Oliver, G. R., Prodduturi, N., Mead, D. W., Hossain, A., Huneke, N. E., Tagtow, C. M. & 43 others, Ailawadhi, S., Ansell, S. M., Banck, M. S., Bryce, A. H., Carballido, E. M., Chanan-Khan, A. A., Curtis, K. K., Resnik, E., Gawryletz, C. D., Go, R. S., Halfdanarson, T. R., Ho, T. H., Joseph, R. W., Kapoor, P., Mansfield, A. S., Meurice, N., Rao, A. A. N., Nowakowski, G. S., Pardanani, A., Parikh, S. A., Cheville, J. C., Feldman, A. L., Ramanathan, R. K., Robinson, S. I., Tibes, R., Finnes, H. D., McCormick, J. B., McWilliams, R. R., Jatoi, A., Patnaik, M. M., Silva, A. C., Wieben, E. D., McAllister, T. M., Rumilla, K. M., Kerr, S. E., Lazaridis, K. N., Farrugia, G., Keith Stewart, A., Clark, K. J., Kennedy, E. J., Klee, E. W., Borad, M. J. & Fernandez-Zapico, M. E., Jan 1 2017, In : JCO Precision Oncology. 2017, 1, p. 1-13 13 p.

Research output: Contribution to journal › Article

Open Access
1 Scopus citations

Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers

de Bono, J., Ramanathan, R. K., Mina, L., Chugh, R., Glaspy, J., Rafii, S., Kaye, S., Sachdev, J., Heymach, J., Smith, D. C., Henshaw, J. W., Herriott, A., Patterson, M., Curtin, N. J., Byers, L. A. & Wainberg, Z. A., Jan 1 2017, In : Cancer discovery. 7, 6, p. 620-629 10 p.

Research output: Contribution to journal › Article

142 Scopus citations

Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors

Weiss, G. J., Jameson, G., von Hoff, D. D., Valsasina, B., Davite, C., Di Giulio, C., Fiorentini, F., Alzani, R., Carpinelli, P., Di Sanzo, A., Galvani, A., Isacchi, A. & Ramanathan, R. K., Jul 20 2017, (Accepted/In press) In : Investigational New Drugs. p. 1-11 11 p.

Research output: Contribution to journal › Article

10 Scopus citations

Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors

Juric, D., Krop, I., Ramanathan, R. K., Wilson, T. R., Ware, J. A., Sanabria Bohorquez, S. M., Savage, H. M., Sampath, D., Salphati, L., Lin, R. S., Jin, H., Parmar, H., Hsu, J. Y., Von Hoff, D. D. & Baselga, J., Jul 2017, In : Cancer discovery. 7, 7, p. 704-715 12 p.

Research output: Contribution to journal › Article

61 Scopus citations

Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis

Borazanci, E., Millis, S. Z., Kimbrough, J., Doll, N., von Hoff, D. & Ramanathan, R. K., 2017, In : Journal of Gastrointestinal Oncology. 8, 1, p. 164-172 9 p.

Research output: Contribution to journal › Article

19 Scopus citations

Recent advances in the treatment of pancreatic adenocarcinoma

Braiteh, F., Ramanathan, R. K. & Bekaii-Saab, T., Nov 1 2017, In : Clinical Advances in Hematology and Oncology. 15, 11, p. 1-2 2 p.

Research output: Contribution to journal › Article

Recent advances in the treatment of pancreatic adenocarcinoma: Further observations

Ramanathan, R. K. & Bekaii-Saab, T., Nov 1 2017, In : Clinical Advances in Hematology and Oncology. 15, 11, 1 p.

Research output: Contribution to journal › Comment/debate

Relative contribution of baseline variables in a nomogram to predict survival in patients treated with nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer

Goldstein, D., Von Hoff, D., Chiorean, E., Reni, M., Tabernero, J., Ramanathan, R., Wilkerson, J., Botteman, M., Aly, A., Margunato-Debay, S., Lu, B., Louis, C., Renschler, M., McGovern, D. & Lee, C., Jun 1 2017, In : Annals of oncology : official journal of the European Society for Medical Oncology. 28, p. iii142-iii144

Research output: Contribution to journal › Article

Open Access
9 Scopus citations

Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis

Sonbol, M. B., Firwana, B., Wang, Z., Almader-Douglas, D., Borad, M. J., Makhoul, I., Ramanathan, R. K., Ahn, D. & Bekaii-Saab, T., Dec 1 2017, In : Cancer. 123, 23, p. 4680-4686 7 p.

Research output: Contribution to journal › Article

12 Scopus citations

Targeting the stroma in pancreatic cancer

Ahn, D. & Ramanathan, R. K., Dec 1 2017, In : Chinese Clinical Oncology. 6, 6, 65.

Research output: Contribution to journal › Review article

2 Scopus citations

Tumor reduction in primary andmetastatic pancreatic cancer lesions with nab-paclitaxel and gemcitabine: An exploratory analysis from a phase 3 study

Kunzmann, V., Ramanathan, R. K., Goldstein, D., Liu, H., Ferrara, S., Lu, B., Renschler, M. F. & Von Hoff, D. D., 2017, In : Pancreas. 46, 2, p. 203-208 6 p.

Research output: Contribution to journal › Article

13 Scopus citations

Virotherapies in pancreatic cancer

Ahn, D. & Ramanathan, R. K., Sep 27 2017, Current and Emerging Therapies in Pancreatic Cancer. Springer International Publishing, p. 309-322 14 p.

Research output: Chapter in Book/Report/Conference proceeding › Chapter

2016

A Case Report of Ischemic Stroke in a Patient with Metastatic Gastric Cancer Secondary to Treatment with the Vascular Endothelial Growth Factor Receptor-2 Inhibitor Ramucirumab

Christiansen, M. E., Ingall, T., Lew, E. C., Ramanathan, R. K. & Paripati, H. R., Jan 1 2016, In : Case Reports in Oncology. 9, 2, p. 317-320 4 p.

Research output: Contribution to journal › Article

1 Scopus citations

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

Chiorean, E. G., Von Hoff, D. D., Reni, M., Arena, F. P., Infante, J. R., Bathini, V. G., Wood, T. E., Mainwaring, P. N., Muldoon, R. T., Clingan, P. R., Kunzmann, V., Ramanathan, R. K., Tabernero, J., Goldstein, D., McGovern, D., Lu, B. & Ko, A., Apr 1 2016, In : Annals of Oncology. 27, 4, p. 654-660 7 p., mdw006.

Research output: Contribution to journal › Article

44 Scopus citations

Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: A cohort study

Kasi, P. M., Kotani, D., Cecchini, M., Shitara, K., Ohtsu, A., Ramanathan, R. K., Hochster, H. S., Grothey, A. F. & Yoshino, T., Jul 13 2016, In : BMC Cancer. 16, 1, 467.

Research output: Contribution to journal › Article

35 Scopus citations

Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers

Borad, M. J., Egan, J. B., Condjella, R. M., Liang, W. S., Fonseca, R., Ritacca, N. R., McCullough, A. E., Barrett, M., Hunt, K. S., Champion, M. D., Patel, M. D., Young, S. W., Silva, A. C., Ho, T. H., Halfdanarson, T. R., Mc Williams, R. R., Lazaridis, K. N., Ramanathan, R. K., Baker, A., Aldrich, J. & 17 others, Kurdoglu, A., Izatt, T., Christoforides, A., Cherni, I., Nasser, S., Reiman, R., Cuyugan, L., McDonald, J., Adkins, J., Mastrian, S. D., Valdez, R., Jaroszewski, D. E., Von Hoff, D. D., Craig, D. W., Stewart, A. K., Carpten, J. D. & Bryce, A. H., 2016, In : Scientific Reports. 6, 1, 25.

Research output: Contribution to journal › Article

11 Scopus citations

Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)

Goldstein, D., Von Hoff, D. D., Moore, M., Greeno, E., Tortora, G., Ramanathan, R. K., Macarulla, T., Liu, H., Pilot, R., Ferrara, S. & Lu, B., Jan 1 2016, In : European Journal of Cancer. 52, p. 85-91 7 p.

Research output: Contribution to journal › Article

17 Scopus citations

Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: Phase III MPACT trial

Scheithauer, W., Ramanathan, R. K., Moore, M., Macarulla, T., Goldstein, D., Hammel, P., Kunzmann, V., Liu, H., McGovern, D., Romano, A. & Von Hoff, D. D., Jun 1 2016, In : Journal of Gastrointestinal Oncology. 7, 3, p. 469-478 10 p.

Research output: Contribution to journal › Article

22 Scopus citations

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

Patnaik, A., Appleman, L. J., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Weiss, G. J., Sachdev, J. C., Chadha, M., Fulk, M., Ejadi, S., Mountz, J. M., Lotze, M. T., Toledo, F. G. S., Chu, E., Jeffers, M., Peña, C., Xia, C., Reif, S., Genvresse, I. & 1 others, Ramanathan, R. K., Jan 1 2016, In : Annals of Oncology. 27, 10, p. 1928-1940 13 p.

Research output: Contribution to journal › Article

Open Access
81 Scopus citations

Hepatoid carcinoma of the pancreas: Case report, next-generation tumor profiling, and literature review

Chang, J. M., Katariya, N. N., Lam-Himlin, D. M., Haakinson, D. J., Ramanathan, R. K., Halfdanarson, T. R., Borad, M. J., Pannala, R., Faigel, D., Moss, A. A. & Mathur, A. K., Oct 6 2016, In : Case Reports in Gastroenterology. 10, 3, p. 605-612 8 p.

Research output: Contribution to journal › Review article

4 Scopus citations

Metastatic pancreatic cancer: American Society of Clinical Oncology clinical practice guideline

Sohal, D. P. S., Mangu, P. B., Khorana, A. A., Shah, M. A., Philip, P. A., O'Reilly, E. M., Uronis, H. E., Ramanathan, R. K., Crane, C. H., Engebretson, A., Ruggiero, J. T., Copur, M. S., Lau, M., Urba, S. & Laheru, D., Aug 10 2016, In : Journal of Clinical Oncology. 34, 23, p. 2784-2796 13 p.

Research output: Contribution to journal › Review article

126 Scopus citations